Rosiglitazone maleate with metformin hydrochloride
PBAC's latest decision on Rosiglitazone maleate with metformin hydrochloride: Recommended with restriction (2006). Considered for type 2 diabetes mellitus, for use in combination therapy or as part of triple therapy when used in combination with a sulfonylurea, and for initiation of therapy where blood glucose concentrations are inadequately controlled on maximally tolerated doses of metformin.
PBAC outcome
Recommended with restriction
Authority required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2006
Submissions
1
2006 → 2006
Eligible population
type 2 diabetes mellitus patients with inadequate glycaemic control despite using metformin alone, or metformin in combination with a sulfonylurea
Therapy area
Diabetes
Evidence base
RCT
Primary endpoint
HbA1c
Key trials
Bailey et al, 2005, Weissman et al, 2005
Comparator
concomitant rosiglitazone and metformin taken as individual tablets
Economic model
Cost-minimisation
ICER note
Cost-minimisation approach used; no modelled economic evaluation presented